Solving equity & access issues on life-saving health tools like vaccines & treatments is critical as the 🌍 prepares for future disease outbreaks. Met with IFPMA's leadership, Thomas B. Cueni & Jean-Christophe Tellier, to discuss these opportunities, building on #COVID19 lessons.

A productive discussion with WHO DG Tedros Adhanom Ghebreyesus & team. Covered #COVID19 response, solution for vaccine equity for future pandemics, health systems strengthening, #UHC and #AMR , all areas where biopharmaceutical industry know-how and collaboration is key to meeting shared goals.

On margins of #WorldBioSummit , Fumie Griego, Ph.D. spoke with The Korea Herald 코리아헤럴드 about what enables an #innovation framework and the importance of a robust regulatory system⤵️
koreaherald.com/view.php?ud=20…

Friends’ board chair Jeffrey L Sturchio hosts a BCIU panel with Atul Gawande Dr. Jane Ruth Aceng Ocero Dr Matshidiso Moeti and Dr. Allan Pamba focusing on how the world can build up diagnostic capacity to fight the diseases of today as well as tomorrow

It was a pleasure to be a partner in this event to celebrate the The Global Fund achievements. We Roche remain committed to the fight against HIV, TB and Malaria, in order to achieve the UN Sustainable Development Goals and the UNAIDS 95-95-95 targets.

Swift #pathogensharing , an enabling #innovation ecosystem, multilateral partnerships & regulatory agility are among the #C19LessonsLearned that must be implemented to fight against future unknown diseases.

Joint statement delivered WHO/Europe #RC72 : ifpma.info/3DcyMAo

With GISAID Initiative & other initiatives, we have the infrastructure to ensure #pathogen sahring . Now, leaders worldwide🌏must commit to promote rapid access to #pathogen information for faster & better global pandemic responses. #ShareDataOnPathogens

COVID-19 taught us many lessons. Science and production delivered, but efforts to achieve equitable access must continue. We’re working on solutions for when the next outbreak happens. Learn how we’re #AlwaysInnovating team-vaccines.ifpma.org/covid-19-solut… #TeamVaccines

The biopharma industry supports the The Global Fund 7th replenishment investment case and commits to building upon lessons learned during the #COVID19 pandemic to strengthen health systems worldwide ➡️ ifpma.info/3TEiu9g

Marie-Ange Saraka-Yao from Gavi Gavi, the Vaccine Alliance tells the #H20Summit that a co-ordinating mechanism is important for just-in-time information during a health emergency but it must allow for nimbleness and flexibility.

The #H20Summit panel on #AMR is just starting, with opening remarks from the great HananBalkhyحنان بلخي. CEO Henry Skinner is among the panelists and IFPMA’s James Anderson will give concluding remarks. Tune in now with the live stream via G20 Health & Development Partnership: youtube.com/watch?v=7uL0h3…

James Anderson, Executive Director for Global Health IFPMA is summing up the panel discussion on AMR. He says we need to prepare for the next health emergency and that is not the same as preparing for a repeat of Covid

#H20Summit

We were honored to welcome Shannon Resetich, Durhane Wong-Rieger, Fumie Griego and Alexander Natz (moderator) to discuss the importance of public private partnerships to shape the future of rare diseases around the world. #WorldOrphanUSA #patientadvocacy #raredisease #orphandrugs

Delighted to be at #WorldOrphanUSA to affirm IFPMA’s commitment to work with @RDI and other global health stakeholders to advocate for more patient-centric policies and robust health systems to bring innovation to patients at the multilateral level.

After the loss of my mum to #cervicalcancer , I’m proud to play my part in improving access to potentially life-saving vaccines that help prevent others from losing loved ones as I did. teamvaccines.ifpma.org/weerawat-story #VaccinesForLife #TeamVaccines

We are committed to cultivating #ClinicalResearch representative of those it serves.

Join us in a webinar discussing how #youth in the industry seek innovative approaches to improve #ClinicalTrials .

⏰ 02 June, 14:00-15:30 CET
💻 bit.ly/3KEDmrp
#YouthPerspectives

As demonstrated in a recent The Lancet study, #AntimicrobialResistance (AMR) killed over 1.2 million people around the🌍in 2019.

IFPMA DG, Thomas B. Cueni explains how financial incentives can bridge the gap between #innovation & access to #beatAMR ⤵️

AORTIC The Max Foundation Project ECHO National Comprehensive Cancer Network (NCCN) MedicinesPatentPool BeiGene ASCO Access to Medicine Foundation Union for International #CancerControl Thomas B. Cueni IFPMA & its members are eager to contribute to this new multi-stakeholder model & ready to co-create new solutions for access to cancer meds
AstraZeneca, Bayer AG, Bristol Myers Squibb, Daiichi Sankyo, MSD, Novartis, @Pfizer, Roche, Sanofi, Takeda Pharmaceutical Teva Pharmaceuticals & Gilead Sciences

Improving health outcomes for people living w/ cancer in LLMICs is a must. But ‘same old’ ways of working won't achieve this goal.

We're proud to be an #ATOMcoalition partner, a🌏initiative working to ensure that cancer patients can receive the care & treatment they need.

Diversity & inclusion in #ClinicalTrials is a matter of both #healthequity and scientific rigor.

Just launched, IFPMA’s policy position on ‘Diversity & Inclusion in Clinical Trials: Bioethical Perspective and Principles’. #clinicaltrialsday

Link➡️ifpma.info/38D5NsJ